Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Livent, Amgen And Some Other Big Stocks Moving Lower On Monday

Author: Lisa Levin | September 12, 2022 11:08am

U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Monday. Here are some big stocks recording gains in today’s session.

  • DICE Therapeutics, Inc. (NASDAQ:DICE) fell 19.6% to $18.20. Stifel, last week, initiated coverage on the stock with a Buy rating and a $37 price target.
  • Entrada Therapeutics, Inc. (NASDAQ:TRDA) dropped 11.4% to $13.21. Entrada Therapeutics, last month, posted a Q2 loss of $0.74 per share.
  • ShiftPixy, Inc. (NASDAQ:PIXY) fell 9.8% to $31.06 after gaining 11% on Friday.
  • Azure Power Global Limited (NYSE:AZRE) dropped 9.3% to $5.32.
  • Immatics N.V. (NASDAQ:IMTX) fell 9% to $11.69.
  • Microvast Holdings, Inc. (NASDAQ:MVST) declined 8.3% to $2.3197.
  • Construction Partners, Inc. (NASDAQ:ROAD) fell 7.8% to $28.00.
  • Forge Global Holdings, Inc. (NYSE:FRGE) dropped 7.8% to $4.04.
  • Burning Rock Biotech Limited (NASDAQ:BNR) declined 7.2% to $3.33.
  • Humacyte, Inc. (NASDAQ:HUMA) fell 7.1% to $4.19. Humacyte recently filed for mixed-securities shelf offering of up to $300 million.
  • Couchbase, Inc. (NASDAQ:BASE) dipped 7.1% to $14.49. The company, last week, posted upbeat quarterly results.
  • Livent Corporation (NYSE:LTHM) fell 5.8% to $32.46 after Verticle Research downgraded the stock from Buy to Hold and announced a $35 price target.
  • Amgen Inc. (NASDAQ:AMGN) dropped 3.7% to $238.44 following FDA approval of Bristol Myers Squibb's plaque psoriasis drug Sotyktu, which showed superior efficacy to Amgen's Otezla.

Posted In: AMGN AZRE BASE BNR DICE FRGE HUMA IMTX LTHM MVST PIXY ROAD TRDA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist